Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_provenance.
- befree-20150227 importedOn "2015-02-27" NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_provenance.
- NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_assertion wasGeneratedBy ECO_0000203 NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_provenance.
- NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_assertion wasDerivedFrom befree-20150227 NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_provenance.
- NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_assertion SIO_000772 17992582 NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_provenance.
- NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_assertion evidence source_evidence_literature NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_provenance.
- NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_assertion description "[Ultimately, molecularly based designer pharmaceuticals may emerge from this research, such as the case of trastuzumab (Herceptin) in HER-2/neu positive breast cancer, and imatinib (Gleevec) in chronic myelocytic leukemia and gastrointestinal stromal tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379014.RAYZp8jbEJCSrDKGWymQ9MkdTB1p9zxgc6PmQvxXh5NgA130_provenance.